The Voluntary Framework on Disclosure was developed by Innovative Medicines Canada. As a partner in Canada’s healthcare system, Novartis Pharmaceuticals Canada Inc. (Novartis) regularly collaborates with healthcare professionals (HCPs) and healthcare organizations (HCOs) to foster scientific exchange, for the ultimate benefit of patients. These collaborations are bound by local and international laws and regulated by Innovative Medicines Canada’s Code of Ethical Practices.
Novartis’ decision to publish our payments to HCPs and HCOs is voluntary and part of our overall commitment to greater transparency and high ethical standards in our business practices. This commitment complements the significant investments we make in research and development across the country, which over the last 5 years, totaled approximately $47 million.
Novartis is proud of the relationships we have with Canadian HCPs, HCOs and other healthcare stakeholders. These relationships are critical to advancing scientific knowledge, education and quality of care for patients. By bringing greater transparency to our work, we hope to foster stronger understanding of our industry’s collaborations across the healthcare sector, and enhance trust in Canada’s healthcare system.
Payment information from January 1, 2021, to December 31, 2021, has been captured in aggregate form (one sum total) and presented below in three categories: